The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in rats

Neuroscience Letters

Volumn 569, Issue , 2014, Pages 104-109

  Rivers Auty, J R ^a   Smith, P F ^a   Ashton, J C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Brain damage; Cannabinoid; GW405833; Hypoxia ischemia

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; LECTIN; 1-(2,3-DICHLOROBENZOYL)-5-METHOXY-2-METHYL-(2-(MOPHOLIN-4-YL)ETHYL)-1H-INDOLE; CNR2 PROTEIN, RAT; INDOLE DERIVATIVE; MORPHOLINE DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; HIPPOCAMPUS; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MACROPHAGE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; THERAPY EFFECT; TREATMENT OUTCOME; AGONISTS; ANIMAL; BRAIN; BRAIN INFARCTION; DRUG EFFECTS; HYPOXIA-ISCHEMIA, BRAIN; MALE; MAZE TEST; PATHOLOGY; PSYCHOLOGY; WISTAR RAT;

ANIMALS; BRAIN; BRAIN INFARCTION; HYPOXIA-ISCHEMIA, BRAIN; INDOLES; MALE; MAZE LEARNING; MORPHOLINES; NEUROPROTECTIVE AGENTS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2;

EID: 84898964318     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.03.077     Document Type: Article

References (22)

1. Acarin L., Vela J.M., Gonzalez B., Castellano B. Demonstration of poly-n-acetyl lactosamine residues in ameboid and ramified microglial cells in rat-brain by tomato lectin-binding. J. Histochem. Cytochem. 1994, 42:1033-1041.
2. Alonso-Alconada D., Alvarez A., Hilario E. Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury. Neurosci. Bull. 2011, 27:275-285.
3. Carmichael S.T. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005, 2:396-409.
4. Clarkson A.N., Huang B.S., Macisaac S.E., Mody I., Carmichael S.T. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 2010, 468:305-309.
5. Fernandez-Lopez D., Martinez-Orgado J., Nunez E., Romero J., Lorenzo P., Moro M.A., Lizasoain I. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res. 2006, 60:169-173.
6. Fernandez-Lopez D., Pazos M.R., Tolon R.M., Moro M.A., Romero J., Lizasoain I., Martinez-Orgado J. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatr. Res. 2007, 62:255-260.
7. Field A. Discovering Statistics Using SPSS 2009, Sage, Los Angeles, CA, USA.
8. Geddes R., Vannucci R.C., Vannucci S.J. Delayed cerebral atrophy following moderate hypoxia-ischemia in the immature rat. Dev. Neurosci. 2001, 23:180-185.
9. Lo E.H. A new penumbra: transitioning from injury into repair after stroke. Nat. Med. 2008, 14:497-500.
10. Lunn C.A., Fine J.S., Rojas-Triana A., Jackson J.V., Fan X.D., Kung T.T., Gonsiorek W., Schwarz M.A., Lavey B., Kozlowski J.A., Narula S.K., Lundell D.J., Hipkin R.W., Bober L.A. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 2006, 316:780-788.
11. Maggo S., Ashton J.C. Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig. Eur. J. Pharmacol. 2014, 723:294-304.
12. 2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 2005, 95:437-445.
13. Murikinati S., Juttler E., Keinert T., Ridder D.A., Muhammad S., Waibler Z., Ledent C., Zimmer A., Kalinke U., Schwaninger M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2009, 24:788-798.
14. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25:1904-1913.
15. Rivers J.R., Ashton J.C. Age matching animal models to humans - theoretical considerations. Curr. Drug Discov. Technol. 2013, 10(3):177-181.
16. Rivers J.R., Ashton J.C. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10:47-64.
17. Rivers J.R., Sutherland B.A., Ashton J.C. Characterization of a rat hypoxia-ischemia model where duration of hypoxia is determined by seizure activity. J. Neurosci. Methods 2011, 197:92-96.
18. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., Whiteside G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy,. Neuropharmacology 2005, 48:658-672.
19. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
20. Zarruk J.G., Fernandez-Lopez D., Garcia-Yebenes I., Garcia-Gutierrez M.S., Vivancos J., Nombela F., Torres M., Burguete M.C., Manzanares J., Lizasoain I., Moro M.A. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 2012, 43:211-219.
21. 2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab. 2007, 27:1387-1396.
22. 2 receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 2008, 152:753-760.